Abstracts tagged "SLE and animal models"

Abstract Number: 2786 • 2016 ACR/ARHP Annual Meeting
The Janus Kinase Inhibitor Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction
Yasuko Furumoto¹, Carolyne K. Smith², Luz P. Blanco³, Wanxia L. Tsai⁴, Wenpu Zhao⁵, Victoria Hoffmann⁶, Seth Thacker⁷, Giuseppe Sciumè⁸, Leti Nuñez¹, Alan Remaley⁹, John J O'Shea¹⁰, Mariana Kaplan¹¹ and Massimo G. Gadina¹², ¹NIAMS NIH, Translational Immunology Section, Office of Science and Technology, Bethesda, MD, ²Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁵NIAMS NIH, Systemic Autoimmunity Branch, Bethesda, MD, ⁶Division of Veterinary Resources, National Institutes of Health, Bethesda, MD, ⁷NHLBI NIH, Lipoprotein Metabolism Section, Bethesda, MD, ⁸NIAMS NIH, Molecular Immunology and Inflammation Branch, Bethesda, MD, ⁹NHLBI, National Institutes of Health, Bethesda, MD, ¹⁰NIAMS NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ¹¹NIAMS/NIH, Bethesda, MD, ¹²Translational Immunology Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Dysregulation of innate and adaptive immune responses contributes to the pathogenesis of systemic lupus erythematosus (SLE) and its associated premature vascular damage. To date,…
Abstract Number: 1948 • 2014 ACR/ARHP Annual Meeting
A Dual Role for IFN-γ in Development of Peripheral B Cells in Lupus-Prone MRL/Lpr Mice
Takeshi Machida¹, Natsumi Sakamoto¹, Gary S. Gilkeson² and Hideharu Sekine¹, ¹Immunology, Fukushima Medical University School of Medicine, Fukushima, Japan, ²Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC
Background/Purpose: It had been reported previously that IFN-gamma and IFN-gamma-receptor-1 (IFNGR1) were required for auto-Ab production and development of renal disease in lupus-prone MRL/lpr mice.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].